金城医药
(300233)
| 流通市值：47.09亿 | | | 总市值：48.87亿 |
| 流通股本：3.70亿 | | | 总股本：3.84亿 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 2,515,318,391.16 | 1,758,578,253.52 | 931,696,552.76 | 3,538,312,459.65 |
| 营业收入 | 2,515,318,391.16 | 1,758,578,253.52 | 931,696,552.76 | 3,538,312,459.65 |
| 二、营业总成本 | 2,333,206,417.21 | 1,604,450,464.21 | 824,597,996.18 | 3,293,667,808.57 |
| 营业成本 | 1,505,877,666.08 | 1,044,273,476.63 | 517,103,996.16 | 1,991,127,087.91 |
| 税金及附加 | 29,272,625.07 | 20,198,433.4 | 10,418,858.11 | 36,155,248.75 |
| 销售费用 | 389,547,908.92 | 278,049,225.02 | 171,862,174.54 | 680,647,573.8 |
| 管理费用 | 284,393,309.03 | 182,345,526.22 | 88,039,447.4 | 390,750,791.04 |
| 研发费用 | 122,556,886.36 | 81,580,181.77 | 37,715,121.84 | 184,708,538.25 |
| 财务费用 | 1,558,021.75 | -1,996,378.83 | -541,601.87 | 10,278,568.82 |
| 其中:利息费用 | 14,547,591.78 | 10,070,636.55 | 4,851,607.94 | 24,924,241.76 |
| 其中:利息收入 | 10,449,035.67 | 7,475,001.15 | 3,996,286.93 | 14,592,685.12 |
| 加:公允价值变动收益 | -305,092.09 | 464,427.06 | 203,056.53 | -81,540.57 |
| 加:投资收益 | -1,524,342.93 | -2,171,637.17 | -164,341.19 | 590,132.95 |
| 资产处置收益 | 1,560,628.81 | 1,370,589.59 | 173,415.58 | -2,156,299.76 |
| 资产减值损失(新) | -10,161,619.9 | -7,203,414.23 | -63,981.56 | -46,542,833.7 |
| 信用减值损失(新) | 4,462,563.61 | 2,623,981.55 | 2,270,345.38 | -4,807,335.75 |
| 其他收益 | 19,122,240.82 | 13,559,537.23 | 6,132,520.85 | 34,202,442.64 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 195,266,352.27 | 162,771,273.34 | 115,649,572.17 | 225,849,216.89 |
| 加:营业外收入 | 2,175,423.89 | 1,554,331.99 | 71,925.52 | 983,971.32 |
| 减:营业外支出 | 500,156.65 | 325,765.45 | 166,741.38 | 1,425,648.26 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 196,941,619.51 | 163,999,839.88 | 115,554,756.31 | 225,407,539.95 |
| 减:所得税费用 | 34,840,797.3 | 25,037,355.05 | 26,395,828.26 | 32,096,540.84 |
| 六、净利润 | 162,100,822.21 | 138,962,484.83 | 89,158,928.05 | 193,310,999.11 |
| 持续经营净利润 | 162,100,822.21 | 138,962,484.83 | 89,158,928.05 | 193,310,999.11 |
| 归属于母公司股东的净利润 | 151,053,816.96 | 130,591,570.91 | 82,971,349.76 | 174,709,358.21 |
| 少数股东损益 | 11,047,005.25 | 8,370,913.92 | 6,187,578.29 | 18,601,640.9 |
| (一)基本每股收益 | 0.4 | 0.34 | 0.22 | 0.45 |
| (二)稀释每股收益 | 0.4 | 0.34 | 0.22 | 0.45 |
| 八、其他综合收益 | - | - | - | 1,705,202.58 |
| 归属于母公司股东的其他综合收益 | - | - | - | 1,705,202.58 |
| 九、综合收益总额 | 162,100,822.21 | 138,962,484.83 | 89,158,928.05 | 195,016,201.69 |
| 归属于母公司股东的综合收益总额 | 151,053,816.96 | 130,591,570.91 | 82,971,349.76 | 176,414,560.79 |
| 归属于少数股东的综合收益总额 | 11,047,005.25 | 8,370,913.92 | 6,187,578.29 | 18,601,640.9 |
| 公告日期 | 2024-10-25 | 2024-08-23 | 2024-04-25 | 2024-03-29 |
| 审计意见(境内) | | | | 标准无保留意见 |